Intravitreal infliximab for refractory pseudophakic cystoid macular edema: Results of the Pan-American Collaborative Retina Study Group

被引：35

作者：

Wu L. ^{[1
]}

Fernando Arevalo J. ^{[2
]}

Hernandez-Bogantes E. ^{[1
]}

Roca J.A. ^{[3
]}

机构：

[1] Instituto de Cirugia Ocular, San José

[2] Retina and Vitreous Service, Clinica Oftalmológica, Centro Caracas, Caracas

[3] Clínica Ricardo Palma, Lima

来源：

International Ophthalmology | 2012年 / 32卷 / 3期

关键词：

Cataract surgery; Cystoid macular edema; Infliximab; Intravitreal injection; Tumor necrosis factor;

D O I：

10.1007/s10792-012-9559-8

中图分类号：

学科分类号：

摘要：

Inflammation is themajor etiologic factor in the development of pseudophakic cystoid macular edema (CME). Several soluble mediators of inflammation such as tumor necrosis factor alpha (TNF-α) have been implicated in the pathogenesis of ocular inflammation. The purpose of this study is to report the shortterm visual and anatomic outcomes following intravitreal injections of infliximab in eyes with refractory CME secondary to cataract surgery. An interventional, retrospective study of 7 eyes with refractory CME that were injected with 1 mg of infliximab. The main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 6-month follow-up. At the 6 month follow-up, BCVA improved from 1.14 ± 0.59 logMAR at baseline to 0.51 ± 0.35 logMAR (p = 0.0156). CMT also improved from 584 ± 159 lm at baseline to 327 ± 127 lmat 6 months (p = 0.0111).Nosystemic adverse events were reported in these patients. There was a single episode of uveitis that responded to topical steroids. Inhibition of TNF-a may be beneficial in the treatment of refractory pseudophakic CME. © Springer Science+Business Media B.V. 2012.

引用

页码：235 / 243

页数：8

共 28 条

[1]

Flach A.J., The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery, Transactions of the American Ophthalmological Society, 96, pp. 557-634, (1998)

[2]

Gallego-Pinazo R., Arevalo J.F., Udaondo P., Garcia-Delpech S., Dolz-Marco R., Diaz-Llopis M., Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib, J Ocul Pharmacol Ther, 28, pp. 65-68, (2011)

[3]

Levin D.S., Lim J.I., Update on pseudophakic cystoid macular edema treatment options, Ophthalmology Clinics of North America, 15, 4, pp. 467-472, (2002)

[4]

Stark Jr. W.J., Maumenee A.E., Fagadau W., Datiles M., Baker C.C., Worthen D., Klein P., Auer C., Cystoidmacular edema in pseudophakia, Surv Ophthalmol, 28, SUPPL., pp. 442-451, (1984)

[5]

Miyake K., Ibaraki N., Prostaglandins and cystoid macular edema, Survey of Ophthalmology, 47, 4, (2002)

[6]

Rabinovich C.E., Use of tumor necrosis factor inhibitors in uveitis, Current Opinion in Rheumatology, 19, 5, pp. 482-486, (2007)

[7]

Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., Gomez Vidal M.A., Collantes Estevez E., Ramirez Chamond R., Omar M.M., Aqueous humor and serum tumor necrosis factor-α in clinical uveitis, Ophthalmic Research, 33, 5, pp. 251-255, (2001)

[8]

Tranos P.G., Wickremasinghe S.S., Stangos N.T., Topouzis F., Tsinopoulos I., Pavesio C.E., Macular edema, Survey of Ophthalmology, 49, 5, pp. 470-490, (2004)

[9]

Conway M.D., Canakis C., Livir-Rallatos C., Peyman G.A., Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema, Journal of Cataract and Refractive Surgery, 29, 1, pp. 27-33, (2003)

[10]

Rho D.S., Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac, Journal of Cataract and Refractive Surgery, 29, 12, pp. 2378-2384, (2003)

← 1 2 3 →